Getinge AB agreed to acquire privately held Dutch company Applikon Biotechnology BV for 840 million Swedish kronor in cash.
Under the agreement, the Swedish healthcare company will purchase all of Applikon Biotechnology's outstanding common shares. Getinge could pay up to 630 million kronor in additional earnout fees in 2021-2022 upon the achievement of certain earnings performance in 2020-2021.
Getinge said it does not expect any material impact on its 2020 earnings.
The acquisition, which will be financed through debt, is expected to close during the first quarter of 2020.
Deutsche Bank is Getinge's exclusive financial adviser and NautaDutilh the legal adviser for the deal.
As of Dec. 18, US$1 was equivalent to 9.42 Swedish kronor.